PK of Levofloxacin in MDR-TB Patients
Pharmacokinetics of Levofloxacin in MDR-TB Patients
The emergence and spread of multi-drug resistant and extensively-drug resistant strains of Mycobacterium tuberculosis (MDR/XDR-TB) have posed a great threat to global TB control and elimination, limiting treatment success rate at worrisome 50% for MDR-TB. Among various factors contributing to the development of drug resistance, low drug exposure is well recognized. To overcome this, either new drugs have to be developed or the dose of currently used therapy be optimized, or both. Fluoroquinolones (levofloxacin and moxifloxacin) and aminoglycosides are important drugs in the MDR-TB treatment regimen. Development of acquired drug resistance to these drugs could complicate and narrow down the available options, and further exacerbate to pre-XDR and XDR-TB.
Objective:
The main objective of this prospective clinical study is to understand the pharmacokinetics of levofloxacin in MDR-TB patients, receiving standard dosage (750-1250mg) based on the body weight and correlate drug exposure, with treatment outcomes.
Study design:
A prospective pharmacokinetic study
Study population: 20 MDR-TB patients
Intervention: Patients receive once daily oral dosing of levofloxacin (750-1250mg) based on the body weight, under MDR-TB treatment regimen of Nepal.
Main study parameters/end points:
The pharmacokinetic parameters(Vd, CL, AUC etc.) of levofloxacin are the primary end points of the study. The Cmax/MIC and AUC0-24h/MIC ratios are the best predictive parameters for efficacy of levofloxacin treatment and will be estimated. Pharmacokinetics will be evaluated in plasma and in oral fluid
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Kathmandu
-
Kalimati, Kathmandu, Nepal, 1494
- German Nepal Tuberculosis Project Clinic (GENETUP)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patient with TB, with Mycobacterium tuberculosis by culture/ Gene Xpert
- Patient is 18 years or older with newly diagnosed or previously treated MDR-TB
- Patient with sputum smear positive for acid-fast bacilli or sputum smear negative but Gene Xpert (MTB/RIF) positive, and resistant to both isoniazid and rifampicin
- Patients with MDR-TB receiving levofloxacin as a part of MDR-TB regimen
Exclusion Criteria:
- Patient with neurologic or severe extra-pulmonary manifestations of tuberculosis
- Pregnant women or breast feeding mothers with MDR-TB
- Patients with diminished renal functions or on medications for the treatment of renal disorders
- Body weight <35 kg
- Patients treated with aluminium- and magnesium containing antacids and ferrous sulphates, cimetidine and probenecid, theophylline, warfarin, zidovudine, digoxin or cyclosporine.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
AUC
Tidsramme: Period I (15-30) day and Period II (45-60) day
|
The main objective of this prospective clinical trial is to evaluate the levofloxacin exposures (AUC) of a standard dose (750-1250mg) in plasma and saliva of MDR-TB patients.
|
Period I (15-30) day and Period II (45-60) day
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Jan-Willem Alffenaar, University Medical Center Groningen, University of Groningen
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LFX/V0.1
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Multiresistent tuberkulose
-
Assistance Publique - Hôpitaux de ParisViatris Inc.Har ikke rekruttert ennåAntibiotikaresistens | Mycobacterium Tuberculosis | MDR-TB | Tuberkulose Multi Drug Resistant ActiveFrankrike
-
Boston UniversityUniversity of Florida; WestatTilbaketrukketTuberkulose Multi Drug Resistant Active
-
National Institute of Allergy and Infectious Diseases...Fullført
-
Marco SchiumaASST Fatebenefratelli Sacco; University of Milan; Damien FoundationRekrutteringLinezolid | Tuberkulose Multi Drug Resistant Active | Terapeutisk medikamentovervåking (TDM)Guinea
-
RSUP PersahabatanOtsuka Holdings Co., Ltd.FullførtTuberkulose Multi Drug Resistant Active | Rifampin-resistent lungetuberkulose | Pre-XDR TBIndonesia
-
Harvard University Faculty of MedicineNational Institute of Allergy and Infectious Diseases (NIAID); Brigham... og andre samarbeidspartnereUkjent
-
The Children's Hospital of Zhejiang University...RekrutteringCAR-T celleterapi | Multi-Drug Resistent Nephrotisk SyndromKina
-
The Children's Hospital of Zhejiang University...TilbaketrukketCAR-T celleterapi | Multi-Drug Resistent Nephrotisk SyndromKina
-
The Children's Hospital of Zhejiang University...RekrutteringAutoimmune sykdommer | Systemisk Lupus Erthematosus | IgAN - IgA nefropati | Multi-Drug Resistent Nephrotisk SyndromKina
-
National Institute of Allergy and Infectious Diseases...TilbaketrukketMulti-Drug Resistent Hiv-1-infeksjon | HIV-1 infeksjonForente stater